Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming...
Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December...
Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December...
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The...
Pharming Group provides updates on EMA regulatory review of leniolisib MAA
Pharming Group N.V. has received approval from the U.S. FDA for Joenja (leniolisib), for the treatment of activated phosphoinositide 3-kinase delta (PI3K?) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Pharming Group N.V. (PHAR) touched a new 52-week high of $17.81 during intraday trading Friday, thanks to FDA approval of its immune disorder drug Leniolisib.